SFA
NBIX icon

Sequoia Financial Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Sequoia Financial Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Buy
6,351
+1,502
+31% +$223K 0.01% 916
2026
Q1 		$639K Sell
4,849
-894
-16% -$119K ﹤0.01% 1125
2025
Q4 		$815K Buy
5,743
+1,356
+31% +$196K ﹤0.01% 993
2025
Q3 		$616K Buy
4,387
+1,669
+61% +$226K ﹤0.01% 1025
2025
Q2 		$342K Buy
+2,718
New +$312K ﹤0.01% 1196
2025
Q1 		– Sell
-1,780
Closed -$243K – 1436
2024
Q4 		$243K Buy
+1,780
New +$220K ﹤0.01% 1125
2024
Q3 		– Sell
-1,505
Closed -$207K – 1341
2024
Q2 		$207K Buy
+1,505
New +$206K ﹤0.01% 1091

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sequoia Financial Advisors's NBIX Position: Q2 2026 in Review

Sequoia Financial Advisors increased its Neurocrine Biosciences (NBIX) stake by 31% in Q2 2026, buying an estimated $223K and bringing the position to 6,351 shares worth $1.07M. The position accounts for 0.01% of the portfolio, ranked #916.

Sequoia Financial Advisors first reported a position in NBIX in Q2 2024 and has held it in 7 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Sequoia Financial Advisors held 6,351 shares of Neurocrine Biosciences worth $1.07M as of Q2 2026.
  • Sequoia Financial Advisors bought 1,502 Neurocrine Biosciences shares in Q2 2026, an estimated $223K.
  • Neurocrine Biosciences made up 0.01% of Sequoia Financial Advisors's portfolio in Q2 2026, its #916 holding.
  • Sequoia Financial Advisors first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 7 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Sequoia Financial Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.